<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01097356</url>
  </required_header>
  <id_info>
    <org_study_id>2414VV</org_study_id>
    <nct_id>NCT01097356</nct_id>
  </id_info>
  <brief_title>The Effect of Probiotics on the Clearance of the Human Papillomavirus and on Cytological Lesions Caused by the Virus</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universiteit Antwerpen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinical cyotpathology laboratory AML</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universiteit Antwerpen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim: In this project proposition the investigators would like to examine the effect of immune
      modulation by probiotics on the clearance of HPV-infections.

      This study provides a model for viral infection but also for cancer precursors. This would be
      an excellent model (and the only possible short-term model) to examine an effect on cancer
      precursors. Cancer precursors (cytological abnormalities such as L-SIL) are a scientifically
      accepted surrogate endpoint for cervical cancer, for example in HPV-vaccine studies.

      Research question: Does daily intake of probiotics lead to a better immune-response in
      HPV-infected women, i.e. does it facilitate clearance of the virus and/or regression of
      cytological lesions?
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2010</start_date>
  <completion_date type="Anticipated">December 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1.proportion of HPV positives in both arms</measure>
    <time_frame>6months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>2. proportion of regression of LSIL lesion in both arms</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>HPV-related Cytological Abnormalities on PAP Smear (LSIL)</condition>
  <arm_group>
    <arm_group_label>common care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>HPV+ patients with LSIL on their PAP smear, waiting for 6 months to receive a new PAP smear</description>
  </arm_group>
  <arm_group>
    <arm_group_label>probiotic drinkers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HPV+, LSIL patients who will drink the study drink for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>probiotic drinkers</intervention_name>
    <description>HPV+, LSIL patients in this arm will drink the probiotic study drink for a period of 6 months</description>
    <arm_group_label>probiotic drinkers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women with a new LSIL diagnosis an HPV positivity on PAP smear

        Exclusion Criteria:

          -  women over 65

          -  immunocompromised patients (because of disease or drugs)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>veronique verhoeven, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universiteit Antwerpen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Veronique Verhoeven</name>
      <address>
        <city>Wilrijk</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>veronique verhoeven, MD, PhD</last_name>
      <phone>0032 3 265 25 18</phone>
      <email>veronique.verhoeven@ua.ac.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2010</study_first_submitted>
  <study_first_submitted_qc>March 31, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2010</study_first_posted>
  <last_update_submitted>April 22, 2010</last_update_submitted>
  <last_update_submitted_qc>April 22, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2010</last_update_posted>
  <responsible_party>
    <name_title>Professor Veronique Verhoeven</name_title>
    <organization>University of Antwerp</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

